Bulletin 2021-4 Supersedes Bulletin 2021-2

Medical Marijuana Program Bulletin 2021-4

This Bulletin is issued by the Rhode Island Department of Business Regulation (“DBR”), Office of Cannabis Regulation (“OCR”) to provide guidance regarding the mandatory testing and enforcement of all flower products and concentrates including extracts and resins offered for sale at a compassion center.

The Rhode Island Department of Health (RIDOH) has issued licenses for third-party analytical testing laboratories pursuant to 216-RICR-60-05-6 Licensing Analytical Laboratories for Sampling and Testing Medical Marijuana (the “DOH Testing Regulations”). Please be advised that:

All flower products with a harvest date on or after January 14, 2021 must be sampled and tested for potency by a licensed laboratory and labeled pursuant to 230-RICR-80-05-1 § 1.5.3(E)(4) in order to be designated as medical marijuana and be offered for sale at a compassion center.

All extracts, resins and concentrates with a manufactured date on or after March 16, 2021 must be sampled and tested for potency by a licensed laboratory and labeled pursuant to 230-RICR-80-05-1 § 1.5.3(E)(4) in order to be designated as medical marijuana and be offered for sale at a compassion center.

All flower products with a harvest date on or after March 16, 2021 must be sampled and receive passing microbiological testing results from a licensed laboratory pursuant to 230-RICR-80-05-1 § 1.11(A) in order to be designated as medical marijuana and be offered for sale at a compassion center.

All flower products with a harvest date on or after May 24, 2021 must be sampled and receive passing water activity testing results from a licensed laboratory pursuant to 230-RICR-80-05-1 § 1.11(A) in order to be designated as medical marijuana and be offered for sale at a compassion center.

All flower products with a harvest date on or after December 30, 2021 must be sampled and receive passing heavy metals results from a licensed laboratory pursuant to 230-RICR-80-05-1 § 1.11(A) in order to be designated as medical marijuana and be offered for sale at a compassion center.

All extracts, resins and concentrates with a manufactured date on or after December 30, 2021 must be sampled and receive passing heavy metals results by a licensed laboratory and labeled pursuant to 230-RICR-80-05-1 § 1.5.3(E)(4) in order to be designated as medical marijuana and be offered for sale at a compassion center.
This guidance is issued in accordance with Rhode Island General Laws § 21-28.6-1 et seq., and the Rules and Regulations Related to the Medical Marijuana Program Administered by the Department of Business Regulation 230-RICR-80-5-1. This document is intended to provide information and should not replace a thorough reading of the regulations found here: https://rules.sos.ri.gov/regulations/part/230-80-05-1.

All questions regarding required sampling and/or testing should be submitted in writing to DBR.MMPCompliance@dbr.ri.gov with the subject line Sampling/Testing Question. These will be addressed via a public document posted to the Department’s website.

August 30, 2021